GLP-1 Advisor | One Day MD

Updated: October 3, 2026  |  Evidence review: Human clinical trials, systematic reviews, regulatory labeling and longevity research Can Ozempic, Wegovy, Mounjaro or Zepbound slow aging? GLP-1-based medicines have moved far beyond the original weight-loss conversation. Large clinical trials have shown meaningful benefits for cardiovascular outcomes, kidney disease, obesity-related heart failure and obstructive sleep apnea. Those effects could translate into healthier aging for appropriately selected patients. But that is not the same as proving that GLP-1 drugs directly slow the biological aging process or extend the maximum human lifespan. As of 2026, that distinction remains critical. OneDayMD evidence position: GLP-1 medicines should currently be viewed primarily as treatments for obesity, type 2 diabetes and selected obesity-related diseases—not as established anti-aging or lifespan-extension drugs. The strongest longevity ...

GLP-1 & Obesity Medicine Guide • Updated October 2026 Semaglutide, tirzepatide and orforglipron represent three important stages in the evolution of incretin-based medicine: an established injectable GLP-1 receptor agonist, a dual GIP/GLP-1 agonist with greater average weight loss, and a next-generation oral GLP-1 receptor agonist designed to deliver GLP-1 therapy without an injection. But the phrase “best GLP-1 drug” can be misleading. These medicines do not have identical mechanisms, routes of administration, dose scales, indications or clinical-outcome evidence. And the headline weight-loss percentages come from different trials, so they cannot simply be placed in one league table as though the three drugs were tested against each other in a single randomized trial. The current evidence nevertheless gives us a useful framework. Tirzepatide currently has the strongest direct evidence for greater weight loss than semaglutide. Semaglutide remains a benchmark therapy w...